Essayer OR - Gratuit
How CDMOs are Adapting to New mRNA Tech Demands
BioSpectrum Asia
|BioSpectrum Asia August 2022
From 2020, coinciding with the outbreak of COVID-19, there’s been a steady upsurge in demand for new technologies such as messenger RNA (mRNA). Contract development and manufacturing organisations (CDMOs) are compelled to rapidly expand capabilities to cater to this upsurge. Let’s see how CDMOs have prepared for the new wave of technologies on the horizon, and the challenges they faced in welcoming a new era of such technologies.

The COVID-19 pandemic highlighted the successful development and utilisation of mRNA vaccines. This has encouraged biopharmaceutical companies to explore and utilise these technologies for other diseases. There are a significant number of new therapeutic programmes that are based on mRNA and lipids, which is encouraging CDMOs to invest in new expertise to deliver end-to-end solutions.
CDMOs have been building new capacity, while simultaneously building out capabilities, to better prepare for the new wave of technologies. Many CDMOs have invested in new processes and resources to safeguard product integrity, minimise waste, enable safe and efficacious supply to patients without delay.
“In the area of mRNA technology, we have seen CDMOs do almost exclusive internal builds, while others are making strategic acquisitions to develop their mRNA capabilities. Many CDMOs, like the Center for Breakthrough Medicines, are expanding to include this dedicated and segregated capacity. It is extraordinarily complex and a different process from other processes CDMOs are currently running, so you must make sure to segregate these operations as much as possible from your existing manufacturing,” said Joerg Ahlgrimm, President and CEO, Center for Breakthrough Medicines, US.
With mRNA-based drugs witnessing a surge in popularity in such a short time frame, companies supporting their development and manufacturing had to adapt quickly as mRNA- based vaccines required cold chain capabilities and more robust aseptic fillfinish technologies.
Weathering the storm
Cette histoire est tirée de l'édition BioSpectrum Asia August 2022 de BioSpectrum Asia.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE BioSpectrum Asia

BioSpectrum Asia
Collaborative R&D: Partnerships shaping the future of biopharma
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
2 mins
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Quantum Computing: Future of diagnostics is being coded today
A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.
4 mins
BioSpectrum Asia Sep 2025
BioSpectrum Asia
First Pacific woman to serve as public health director in NZ
The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Hugel launches botulinum toxin Letybo in Malaysia
South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Australia designs smart wound monitor to improve chronic infection care
Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Revvity unveils innovative reagent technology to accelerate therapeutics development
US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B
Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education
HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI
Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.
1 min
BioSpectrum Asia Sep 2025
Translate
Change font size